ClinicalTrials.gg
Enrolling by invitationNCT02375165BiomarkersUpdated Nov 22, 2023

Biomarkers for the Detection of Lymphatic Insufficiency

An observational study in Lymphedema, sponsored by Stanford University. Enrolling by invitation. Per ClinicalTrials.gov, last updated 2023-11-22.

Sponsored by Stanford University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
1,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Lymphedema by Stanford University — 4 open to participants now, 4 under way, none of them phase 3. Lymphedema · Stanford University.

Started
2009
with 2 others
Observational
4 of 12
2 open now
Registered
7th of 12
by date

Among the 12 studies in Lymphedema by Stanford University, this one is one of 3 that started in 2009, is one of 4 observational ones, and was the 7th registered.

Lymphedema

529 studies on the registry are indexed under Lymphedema; 129 are open to participants now.

Browse Lymphedema studies →

Open to participants now

4 of the 12 studies in Lymphedema by Stanford University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 84 Lymphedema studies recruiting now, 46 (55%) set no upper age limit and 21 (25%) stop at 75 or younger; 5 take children under 18; 12 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Lymphedema by Stanford University, or all of them as a file.
02

Study summary

Acquired lymphedema is a disease that causes chronic swelling of the limb(s). It is frequently under-recognized or misdiagnosed. This study is designed to lead to the development of an accurate, noninvasive, blood test to allow testing for lymphedema. This approach is particularly useful to investigate relative responses to treatment interventions.

Read the detailed description

The validation of a sensitive and specific biomarker assay for human acquired lymphatic vascular insufficiency would represent a highly significant development for the patient community. Accurate bioassay for the presence of lymphatic vascular insufficiency should help to pave the road for future human clinical trials of experimental drugs and therapies designed to treat human lymphatic diseases. Molecular profiling will be performed in human tissues (skin) obtained by biopsy. The insights gained from these initial analyses will determine the targets for assay in human body fluids (blood).

03

Conditions studied

  • Lymphedema

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients who receive their care within Dr. Rockson's clinic in the Stanford Center for Lymphatic and Venous Disorders may be spoken to about voluntary participation in this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For lymphedema participants:

  • clinical diagnosis of lymphedema of at least 6 months' duration

Control participants:

  • no evidence of lymphedema

Exclusion criteria

Exclusion Criteria

For lymphedema participants:

  • active cancer
  • infection
  • bleeding tendency
  • active coronary artery disease
  • congestive heart failure
  • history of stroke or (TIA)
  • uncontrolled hypertension
  • renal insufficiency (serum creatinine > 1.1)
  • active inflammatory or disease (other than lymphedema)

For control participants:

  • lymph node dissection
  • radiation therapy
  • active inflammatory disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Cohort with lymphedema

    Participants with a history of acquired lymphedema of at least 6 months' duration, will have phlebotomy for serum and plasma.

    Procedure: phlebotomy

  • Cohort without lymphedema

    Healthy volunteers; will have phlebotomy for serum and plasma.

    Procedure: phlebotomy

Interventions

  • Procedurephlebotomy

    phlebotomy for collection of plasma and serum, \~30 cc

    Also known as: venipuncture

06

What researchers measure

Primary outcomes

  1. Biomarkers for the Detection of Lymphatic Vascular Insufficiency

    Time frame: one year

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — to be determined

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Available one year after the last study visit and for one year duration.

Access criteria: Requestors will be required to complete a Data Access Agreement

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Dec 2024 and a completion of Dec 2025. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2015
First posted
Mar 2, 2015
Start
Sep 2009
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2025
Last update
Nov 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02375165
Responsible party
Stanley Rockson (Allan and Tina Neill Professor of Lymphatic Research and Medicine, Stanford University) — Principal investigator
First posted
Mar 2, 2015
Start date
Sep 2009
Primary completion
Dec 2024 (estimated)
Completion
Dec 2025 (estimated)
Last update
Nov 22, 2023

Study contacts

Stanley G Rockson, MD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion